This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

This study has been completed.
Information provided by (Responsible Party):
University of Southern California Identifier:
First received: September 9, 2005
Last updated: May 20, 2014
Last verified: May 2014

This is a research study for patients that have an advanced cancer that is confined mostly to the abdominal cavity and have failed treatment with conventional therapy, or for which no standard treatment exists. The purpose of this study is to determine the dose of a chemotherapy drug (called irinotecan) that can be administered safely into the abdominal cavity. We also wish to identify the side effects of irinotecan when it is administered directly into the abdomen. In this study, we will also determine the levels of irinotecan in the blood and in the abdominal cavity.

Irinotecan is a chemotherapy drug that can decrease the size of several different tumors. It is approved by the FDA for the treatment of colon cancer. It appears that some other chemotherapy drugs are more effective and may have less side effects when they are administered directly into the abdomen.

Condition Intervention Phase
Adenocarcinoma Gastric Cancer Drug: irinotecan Phase 1

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Clinical and Pharmacokinetic Trial of Intra-Peritoneal Irinotecan

Resource links provided by NLM:

Further study details as provided by University of Southern California:

Primary Outcome Measures:
  • To establish the maximum tolerated dose (MTD) of irinotecan when administered by an intra-peritoneal route every three weeks. [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • To determine the pharmacokinetics of intra-peritoneal irinotecan. [ Time Frame: One day ]
  • To determine the toxicity profile of intra-peritoneal irinotecan. [ Time Frame: 30 days after patient receives last dose ]

Enrollment: 42
Study Start Date: September 1999
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Intraperitoneal Irinotecan
Drug: irinotecan
Intraperitoneal Irinotecan given every three weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed recurrent, metastatic, or residual cancer with disease confined mostly to the peritoneal cavity. Patients with asymptomatic extra-peritoneal disease are eligible.
  • Measurable or evaluable disease. Patients with malignant ascites or carcinomatosis only (documented by cytology or during surgery) are eligible. Patients with ovarian cancer and disease manifested only by an elevated CA-125 are also eligible.
  • Adequate hepatic, renal, and bone marrow functions: bilirubin less than or equal to 2.0 mg/dl; creatinine less than or equal to 2.0 mg/dl, alkaline phosphatase less than or equal to 3 x upper limit of normal (uln), AST or ALT less than or equal to 3 x uln; AGC greater than or equal to 1500, platelets greater than or equal to 100,000.
  • SWOG performance status 0-2
  • Fully recovered from acute toxicities from prior surgery, chemotherapy, or radiation therapy.
  • Patients must use an approved method of birth control.

Exclusion Criteria:

  • Medical, social, or psychological factors which could prevent patient from receiving treatment.
  • Prior therapy with intra-peritoneal irinotecan
  • Significant intra-peritoneal adhesions detected clinically or by prior surgical exploration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00183859

United States, California
U.S.C. / Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Sponsors and Collaborators
University of Southern California
Principal Investigator: Syma Iqbal, M.D. U.S.C. / Norris Comprehensive Cancer Center
  More Information

Responsible Party: University of Southern California Identifier: NCT00183859     History of Changes
Other Study ID Numbers: 0C-99-7
Study First Received: September 9, 2005
Last Updated: May 20, 2014

Keywords provided by University of Southern California:
solid tumor
phase I
phase one

Additional relevant MeSH terms:
Stomach Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017